Indian Government Ends Bayer’s Monopoly on Cancer Drug

The Indian government will allow a local company to manufacture a generic version of the cancer drug Nexevar, which is currently patented by Bayer. A Common Dreams post explained that the the government’s ruling is based on a trade law that gives the government power to allow the manufacturing of generic versions of otherwise unaffordable drugs. It enables Natco Pharma to create a version of Nexevar that will cost $176 for 120 tablets. Bayer was charging about $5,600 for the same amount. Bayer spokeswoman Sabina Cusimano told the Associated Press, “We will see if we can further defend our intellectual property rights in India.”